US8809281B2ExpiredUtilityPatentIndex 48
Small peptides and methods for blocking IGE mediated activation of an immune cell
Est. expiryNov 13, 2017(expired)· nominal 20-yr term from priority
A61K 38/00A61P 37/08A61P 43/00A61P 37/02A61P 29/00C07K 5/1013A61P 17/00A61K 45/06A61P 11/02A61K 38/07A61P 1/00A61P 11/00C07K 5/081C07K 7/06A61P 17/06A61P 19/02A61P 11/06A61K 38/06
48
PatentIndex Score
0
Cited by
30
References
2
Claims
Abstract
Methods for treating cutaneous inflammation, are described. Also described is a method for inhibiting the mucous release into airways of a patient, a method for blocking IgE activation of an immune cell, a method for stabilizing the cell membrane of an immune cell, thereby preventing their further involvement in the increased inflammatory response to an IgE antigen challenge, and a method for inhibiting the migration of T-cells. Such methods involve administering to said patient a therapeutically effective amount of a peptide having the formula f-Met-Leu-X, wherein X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1. A method for blocking IgE activation of at least one type of immune cell selected from the group consisting of mast cells and basophils, the method comprising contacting said type of immune cell with an IgE activation blocking effective amount of a peptide or salt thereof, said peptide having the formula f-Met-Leu-X where X is at least one member selected from the group consisting of Tyr, Tyr-Phe (SEQ ID NO: 1), Phe-Phe (SEQ ID NO: 2) and Phe-Tyr (SEQ ID NO: 3).
2. A method for regulating IgE production in a human, the method comprising administering to said human an IgE production inhibiting effective amount of a peptide or salt thereof, said peptide having the formula f-Met-Leu-X where X is at least one member selected from the group consisting of Tyr, Tyr-Phe (SEQ ID NO: 1), Phe-Phe (SEQ ID NO: 2) and Phe-Tyr (SEQ ID NO: 3).Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.